ArticleOncology letters2016
Pristimerin overcomes adriamycin resistance in breast cancer cells through suppressing Akt signaling.
Article in Oncology letters, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 23 citations in OpenAlex.
- Downregulation of PRPS2 inhibits tumor growth of non-small cell lung cancer by suppressing PI3K/AKT signaling.Frontiers in medicine · 2026Article
- Pristimerin Promotes Ubiquitination of HSPA8 and Activates the VAV1/ERK Pathway to Suppress TNBC Proliferation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Anticancer Potential and Molecular Targets of Pristimerin in Human Malignancies.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Pristimerin Exerts Pharmacological Effects Through Multiple Signaling Pathways: A Comprehensive Review.Drug design, development and therapy · 2024Review
- Cellular and Molecular Mechanisms of Pristimerin in Cancer Therapy: Recent Advances.Frontiers in oncology · 2021Review
- Pristimerin inhibits the proliferation of HT1080 fibrosarcoma cells by inducing apoptosis.Oncology letters · 2020Article
- Terpenoids, Cannabimimetic Ligands, beyond theMolecules (Basel, Switzerland) · 2020Review
- Pristimerin Suppressed Breast Cancer Progression via miR-542-5p/DUB3 Axis.OncoTargets and therapy · 2020Article
- Pristimerin Suppresses Trophoblast Cell Epithelial-Mesenchymal Transition via miR-542-5p/EGFR Axis.Drug design, development and therapy · 2020Article
- Zhankuic Acids A, B and C fromBiomolecules · 2019Article
- Pristimerin inhibits glioma progression by targeting AGO2 and PTPN1 expression via miR-542-5p.Bioscience reports · 2019Article
- Pristimerin induces apoptosis of oral squamous cell carcinoma cells via GOncology letters · 2019Article
- Pristimerin enhances the effect of cisplatin by inhibiting the miR‑23a/Akt/GSK3β signaling pathway and suppressing autophagy in lung cancer cells.International journal of molecular medicine · 2019Article
- Anti-Cancer Effects of Pristimerin and the Mechanisms: A Critical Review.Frontiers in pharmacology · 2019Review
- Antitumor effects of pristimerin on human osteosarcoma cells in vitro and in vivo.OncoTargets and therapy · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer remains a major public health problem worldwide. Chemotherapy serves an important role in the treatment of breast cancer. However, resistance to chemotherapeutic agents, in particular, multi-drug resistance (MDR), is a major cause of treatment failure in cancer. Agents that can either enhance the effects of chemotherapeutics or overcome chemoresistance are urgently needed for the treatment of breast cancer. Pristimerin, a quinonemethide triterpenoid compound isolated from Celastraceae and Hippocrateaceae, has been shown to possess antitumor, anti-inflammatory, antioxidant and insecticidal properties. The aim of the present study was to investigate whether pristimerin can override chemoresistance in MCF-7/adriamycin (ADR)-resistant human breast cancer cells. The results demonstrated that pristimerin indeed displayed potent cytocidal effect on multidrug-resistant MCF-7/ADR breast cancer cells, and that these effects occurred through the suppression of Akt signaling, which in turn led to the downregulation of antiapoptotic effectors and increased apoptosis. These findings indicate that use of pristimerin may represent a potentially promising approach for the treatment of ADR-resistant breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.